Adjuvant Chemotherapy, Breast Cancer
Conditions
Brief summary
Breast cancer is the most common cause of cancer death in women. Adjuvant chemotherapy significantly reduces the risk of recurrence of high-risk breast cancer. However, about 30% of patients still have distant metastasis or local recurrence after chemotherapy. Moreover, 60% of patients had 3-4 degrees of adverse drug reactions during chemotherapy. The purpose of the study is to investigate relationship between gut microbiome and adjuvant chemotherapy in early breast cancer patients.
Detailed description
Breast cancer is the most common cause of cancer death in women. Adjuvant chemotherapy significantly reduces the risk of recurrence of high-risk breast cancer. However, about 30% of patients still have distant metastasis or local recurrence after chemotherapy. Moreover, 60% of patients had 3-4 degrees of adverse drug reactions during chemotherapy. The human gut microbiota have been considered the most important microecosystem living in symbiosis with the body. It is identified as a crucial determinant in cancer occurrence and development . Besides, Gut microbial alterations may influence the therapy efficacy and adverse drug event. We collect the fresh tail stool sample 24h before adjuvant chemotherapy and 24h after adjuvant chemotherapy then the composition of intestinal microbiota and subsequent short-term alterations are analysed by 16srRNA sequencing.The purpose of the study is to investigate relationship between gut microbiome and adjuvant chemotherapy in early breast cancer patients.
Interventions
None listed
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histologically diagnosed stage I-III breast cancer; * Plan to receive adjuvant chemotherapy in our hospital; * Sign the informed consent; * Good compliance and willing to follow up.
Exclusion criteria
* Those who have started receiving adjuvant chemotherapy; * Chemotherapy contraindications;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of chemotherapy related adverse reaction | 1 years | chemotherapy related adverse reaction are assessed by CTCAE protocol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival | 5years | the length of time after surgery during which no breast cancer is found |
Countries
China
Outcome results
None listed